InspireMD (NSPR) 10-K 5 Mar 24 2023 FY Annual report Financial data

Cover

Cover - USD ($)	12 Months Ended
	Dec. 31, 2023	Mar. 05, 2024	Jun. 30, 2023
Cover [Abstract]
Document Type	10-K
Amendment Flag	false
Document Annual Report	true
Document Transition Report	false
Document Period End Date	Dec. 31, 2023
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2023
Current Fiscal Year End Date	--12-31
Entity File Number	001-35731
Entity Registrant Name	InspireMD, Inc.
Entity Central Index Key	0001433607
Entity Tax Identification Number	26-2123838
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	4 Menorat Hamaor St.
Entity Address, City or Town	Tel Aviv
Entity Address, Country	IL
Entity Address, Postal Zip Code	6744832
City Area Code	(888)
Local Phone Number	776-6804
Title of 12(b) Security	Common Stock, par value $0.0001 per share
Trading Symbol	NSPR
Security Exchange Name	NASDAQ
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Public Float			$ 46,130,594
Entity Common Stock, Shares Outstanding		23,456,590
Documents Incorporated by Reference [Text Block]	Portions of the Registrant’s definitive proxy statement for its 2024 Annual Meeting of Stockholders, which the Registrant intends to file pursuant to Regulation 14A with the Securities and Exchange Commission not later than 120 days after December 31, 2023, are incorporated by reference into Part III of this Annual Report on Form 10-K
ICFR Auditor Attestation Flag	false
Document Financial Statement Error Correction [Flag]	false
Auditor Firm ID	1309
Auditor Name	Kesselman & Kesselman
Auditor Location	Tel-Aviv, Israel

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands		Dec. 31, 2023	Dec. 31, 2022
CURRENT ASSETS:
Cash and cash equivalents		$ 9,640	$ 4,632
Short-term bank deposits			13,171
Marketable securities		29,383
Accounts receivable:
Trade, net		1,804	1,034
Other		648	213
Prepaid expenses		578	655
Inventory		2,106	1,621
TOTAL CURRENT ASSETS		44,159	21,326
NON-CURRENT ASSETS:
Property, plant and equipment, net		1,060	917
Operating lease right of use assets		1,473	1,554
Fund in respect of employee rights upon retirement		951	856
TOTAL NON-CURRENT ASSETS		3,484	3,327
TOTAL ASSETS		47,643	24,653
Accounts payable and accruals:
Trade		939	659
Other		5,081	4,411
TOTAL CURRENT LIABILITIES		6,020	5,070
LONG-TERM LIABILITIES:
Operating lease liabilities		1,038	1,195
Liability for employee rights upon retirement		1,084	995
TOTAL LONG-TERM LIABILITIES		2,122	2,190
TOTAL LIABILITIES		8,142	7,260
EQUITY:
Common stock, par value $0.0001 per share; 150,000,000 shares authorized at December 31, 2023 and 2022; 21,841,215 and 8,330,918 shares issued and outstanding at December 31, 2023 and 2022, respectively		2	1
Preferred C shares, par value $0.0001 per share; 1,172,000 shares authorized at December 31, 2023 and 2022; 1,718 shares issued and outstanding at December 31, 2023 and 2022;	[1]
Additional paid-in capital		261,000	218,977
Accumulated deficit		(221,501)	(201,585)
Total equity		39,501	17,393
Total liabilities and equity		$ 47,643	$ 24,653
[1]Represents an amount less than $1

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2023	Dec. 31, 2022
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	150,000,000	150,000,000
Common stock, shares issued	21,841,215	8,330,918
Common stock, shares outstanding	21,841,215	8,330,918
Series C Preferred Stock [Member]
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	1,172,000	1,172,000
Preferred stock, shares issued	1,718	1,718
Preferred stock, shares outstanding	1,718	1,718

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Income Statement [Abstract]
REVENUES	$ 6,205	$ 5,171
COST OF REVENUES	4,398	4,054
GROSS PROFIT	1,807	1,117
OPERATING EXPENSES:
Research and development	7,981	7,810
Selling and marketing	3,865	3,664
General and administrative	11,104	8,356
Total operating expenses	22,950	19,830
LOSS FROM OPERATIONS	(21,143)	(18,713)
FINANCIAL INCOME , net:	1,292	250
LOSS BEFORE TAX EXPENSES	(19,851)	(18,463)
TAX EXPENSES	65	28
NET LOSS	$ (19,916)	$ (18,491)
NET LOSS PER SHARE - basic	$ (0.82)	$ (2.35)
NET LOSS PER SHARE - diluted	$ (0.82)	$ (2.35)
WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK USED IN COMPUTING NET LOSS PER SHARE - basic	24,268,181	7,871,814
WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK USED IN COMPUTING NET LOSS PER SHARE - diluted	24,268,181	7,871,814

Consolidated Statements of Chan

Consolidated Statements of Changes in Equity - USD ($) $ in Thousands	Common Stock [Member]		Preferred Stock [Member] Series C Convertible Preferred Stock [Member]		Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Beginning balance, value at Dec. 31, 2021	$ 1			[1]	$ 216,625	$ (183,094)	$ 33,532
Balance, shares at Dec. 31, 2021	8,296,256		1,718
Net loss						(18,491)	(18,491)
Share-based compensation related to stock, restricted stock, restricted stock units and stock options award, net of forfeitures					2,352		2,352
Share-based compensation related to stock, restricted stock, restricted stock units and stock options award, net of forfeitures, shares	34,662
Ending balance, value at Dec. 31, 2022	$ 1			[2]	218,977	(201,585)	17,393
Balance, shares at Dec. 31, 2022	8,330,918		1,718
Net loss						(19,916)	(19,916)
Share-based compensation related to stock, restricted stock, restricted stock units and stock options award, net of forfeitures		[2]			4,490		4,490
Share-based compensation related to stock, restricted stock, restricted stock units and stock options award, net of forfeitures, shares	2,936,767
Exercise of pre-funded warrants		[2]
Exercise of pre-funded warrants, shares	307,260						307,260
Issuance of common shares, pre-funded warrants and warrants, net of $4,635 issuance costs	$ 1				37,533		$ 37,534
Issuance of common shares, pre-funded warrants and warrants, net of $4,635 issuance costs, shares	10,266,270						7,731,618
Ending balance, value at Dec. 31, 2023	$ 2			[2]	$ 261,000	$ (221,501)	$ 39,501
Balance, shares at Dec. 31, 2023	21,841,215		1,718
[1]Represents an amount less than $1[2]Represents an amount less than $1

Consolidated Statements of Ch_2

Consolidated Statements of Changes in Equity (Parenthetical) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Statement of Stockholders' Equity [Abstract]
Shares, restricted stock award, forfeited	29,695	10,832
Payments of stock issuance costs	$ 4,635

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (19,916)	$ (18,491)
Adjustments required to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	232	188
Gain from sale of property, plant and equipment	(6)
Change in fair value of markable securities, net of interest received	(739)
Change in liability for employees rights upon retirement	89	(57)
Other financial expense	58	131
Change in operating right of use asset and operating leasing liability	62	(60)
Share-based compensation expenses	4,490	2,352
Decrease (increase) in interest receivable on short term deposits	171	(135)
Loss (gain) on amounts funded in respect of employee rights upon retirement, net	(16)	135
Changes in operating asset and liability items:
Decrease in prepaid expenses	77	7
Decrease (increase) in trade receivables	(770)	190
Increase in other receivables	(435)	(48)
Increase in inventory	(485)	(478)
Increase (decrease) in trade payables	280	(234)
Increase in other payables	532	958
Net cash used in operating activities	(16,376)	(15,542)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of property, plant and equipment	(381)	(473)
Proceeds from sale of property, plant and equipment	12
Investment in short-term bank deposits	(5,500)	(19,000)
Investments in marketable securities	(34,644)
Proceeds from matured marketable securities	6,000
Amounts funded in respect of employee rights upon retirement	(79)	(86)
Withdrawal from short-term bank deposits	18,500	28,000
Net cash provided by (used in) investing activities	(16,092)	8,441
CASH FLOWS FROM FINANCING ACTIVITIES:
Issuance costs of At The Market offering		(140)
Proceeds from issuance of shares and warrants net of $4,635 issuance costs,	37,534
Net cash provided by (used in) financing activities	37,534	(140)
EFFECT OF EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS	(58)	(131)
INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS	5,008	(7,372)
BALANCE OF CASH AND CASH EQUIVALENTS AT BEGINNING OF YEAR	4,632	12,004
BALANCE OF CASH AND CASH EQUIVALENTS AT END OF YEAR	9,640	4,632
SUPPLEMENTAL NON-CASH INVESTING AND FINANCING ACTIVITIES:
Acquisition of right-of-use assets by means of lease liabilities	419	835
Non-cash lease incentive	45
Decrease in right-of-use assets and lease liabilities due to shortening lease term	$ 131

Consolidated Statements of Ca_2

Consolidated Statements of Cash Flows (Parenthetical) $ in Thousands	12 Months Ended
	Dec. 31, 2023 USD ($)
Statement of Cash Flows [Abstract]
Payments of stock issuance costs	$ 4,635

DESCRIPTION OF BUSINESS

DESCRIPTION OF BUSINESS	12 Months Ended
	Dec. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
DESCRIPTION OF BUSINESS	NOTE 1 - DESCRIPTION OF BUSINESS a. General InspireMD, Inc., a Delaware corporation (the “Company”), together with its subsidiaries, is a medical device company focusing on the development and commercialization of its proprietary MicroNet™ stent platform technology for the treatment of complex vascular and coronary disease. MicroNet, a micron mesh sleeve, is wrapped over a stent to provide embolic protection in stenting procedures. The Company’s carotid product (CGuard™ EPS) combines MicroNet and a self-expandable nitinol stent in a single device to treat carotid artery disease. The Company ceased sales of the Company’s MGuard Prime EPS in the beginning of 2022. The Company market its products through distributors in international markets, mainly in Europe. As of the date of issuance of these consolidated financial statements, the Company has the ability to fund its planned operations for at least the next 12 months. However, the Company expects to continue incurring losses and negative cash flows from operations until its product, CGuard™ EPS, reaches commercial profitability. Therefore, in order to fund the Company’s operations until such time that the Company can generate substantial revenues, the Company may need to raise additional funds. b. Status of European Medical Device Regulation for marketing CGuard EPS in countries requiring the CE Mark. For the European Union (“EU”) nations, medical devices must obtain a CE mark before they may be placed on the market. In order to obtain and maintain the CE mark, the Company must comply with EU law on medical devices, which, until May 26, 2021 was governed by the Medical Device Directive 93/42/EEC (“MDD”), by presenting comprehensive technical files for the Company’s products demonstrating safety and efficacy of the product to be placed on the market and passing initial and annual quality management system audit as per ISO 13485 standard by a European Notified Body. The Company has obtained ISO 13485 quality system certification and CGuard EPS that the Company currently distribute into the European Union, displays the required CE mark. In order to maintain certification, the Company is required to pass an annual surveillance audit conducted by Notified Body auditors. The European Union replaced the MDD with the new European Medical Device Regulation (MDR 2017/745) (“MDR”) regulations. The MDR entered into force after a transitional period of three years and a one year extension of that transition period due to the COVID-19 pandemic on May 26, 2021 and which changes several aspects of the regulatory framework in the EU. Manufacturers had the duration of the transition period to update their technical documentation and processes to meet the new requirements in order to obtain a CE Mark. In the Company’s specific case, the Company’s CE mark for CGuard EPS under the MDD expired on November 12, 2022. On February 14, 2023, the Company received a derogation per Article 97 paragraph 1 of Regulation 2017/745 from the Agency for Medicines and Health Products (FAMHP) allowing the Company to continue marketing CGuard EPS in the EU until August 15, 2023. Subsequently, on March 20, 2023 Regulation (EU) 2023/607 was published allowing the Company to continue marketing CGuard EPS in EU countries under the MDD directive until December 31, 2027. In January 2024, the Company received CE mark recertification for the CGuard™ EPS under the EU’s Medical Device Regulation regulatory framework and can market Cguard permanently in EU countries as long as the Company is able to maintain its regulatory approvals. c. Risks Related to Our Operations in Israel including the recent attack by Hamas and other terrorist organizations from the Gaza Strip and Israel’s war against them. In October 2023, Israel was attacked by a terrorist organization and entered a state of war. As of the date of these consolidated financial statements, the war in Israel is ongoing and continues to evolve. The Company operations including the production facility are located in Israel. Currently, such activities in Israel remain largely unaffected. During the year ended December 31, 2023, the impact of this war on the Company’s results of operations and financial condition was immaterial, but such impact may increase, which could be material, as a result of the continuation, escalation or expansion of such war. d. Risks Related to the Geopolitical and Military Tensions Between Russia and Ukraine in Europe The Company derived approximately 13.5 12.1 As a result of the crisis in Ukraine, the United States and the EU have implemented sanctions against certain Russian individuals and entities and have made it more difficult for the Company to collect on outstanding accounts receivable from customers in this region. The Company cannot provide assurance that potential future changes in sanctions will not have a material impact on the Company’s operations in Russia and Belarus or on the Company’s financial results. INSPIREMD, INC. NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

SIGNIFICANT ACCOUNTING POLICIES

SIGNIFICANT ACCOUNTING POLICIES	12 Months Ended
	Dec. 31, 2023
Accounting Policies [Abstract]
SIGNIFICANT ACCOUNTING POLICIES	NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES a. Use of estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates using assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates. As applicable to these consolidated financial statements, the most significant estimates and assumptions relate to inventory valuations and assessing the likelihood of exercise of options to extend the lease term. b. Functional currency The currency of the primary economic environment in which the operations of the Company and its subsidiaries are conducted is the U.S. dollar (“$” or “dollar”). Accordingly, the functional currency of the Company and its subsidiaries is the U.S. dollar. The dollar figures are determined as follows: transactions and balances originally denominated in dollars are presented in their original amounts. Balances in foreign currencies are translated into dollars using historical and current exchange rates for non-monetary and monetary balances, respectively. The resulting translation gains or losses are recorded as financial income or expense, as appropriate. For transactions reflected in the statements of operations in foreign currencies, the exchange rates at transaction dates are used. Depreciation and changes in inventories and other changes deriving from non-monetary items are based on historical exchange rates. c. Principles of consolidation The consolidated financial statements include the accounts of the Company and of its subsidiaries. Intercompany transactions and balances have been eliminated upon consolidation. d. Cash and cash equivalents The Company considers all highly liquid investments purchased with original maturities of three months or less from the purchase date to be cash equivalents. As of December 31, 2023, cash and cash equivalents consisted of cash, short-term deposits (up to three months from the date of deposit) and money market funds. As of December 31, 2022, this balance consisted solely of cash. e. Marketable securities Marketable securities consist of debt securities. The Company elected the fair value option to measure and recognize its investments in debt securities in accordance with ASC 825, Financial Instruments as the Company manages its portfolio and evaluates the performance on a fair value basis. Changes in fair value, realized gains and losses on sales of marketable securities, are reflected in the statements of operation as finance expense (income), net. Marketable securities are classified under current assets in the consolidated balance sheet as they represent the investment of funds available for the Company’s current operations. INSPIREMD, INC. NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued) NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES f. Short-term bank deposits Bank deposits with original maturities of more than three months but less than one year are presented as part of short-term bank deposits. Deposits are presented at their cost which approximates market values including accrued interest. Interest on deposits is recorded as financial income. g. Concentration of credit risk and allowance for doubtful accounts Financial instruments that may potentially subject the Company to a concentration of credit risk consist of cash and cash equivalents and short-term bank deposits, which are deposited in major financially sound institutions in the U.S, Israel and Germany, and trade accounts receivable and other receivables. The Company’s trade accounts receivable is derived from revenues earned from customers from various countries. The Company performs ongoing credit evaluations of its customers’ financial condition and, requires no collateral from its customers. The Company also has a credit insurance policy for some of its customers. The Company maintains the allowance for estimated losses resulting from the inability of the Company’s customers to make required payments. The allowance represents the current estimate of lifetime expected credit losses over the remaining duration of existing accounts receivable considering current market conditions and supportable forecasts when appropriate. The estimate is a result of the Company’s ongoing evaluation of collectability, customer creditworthiness, historical levels of credit losses, and future expectations. The allowance for expected credit losses was immaterial during the periods presented. h. Inventory Inventories are stated at the lower of cost (cost is determined on a “first-in, first-out” basis) or net realizable value. The Company’s inventories generally have a limited shelf life and are subject to impairment as they approach their expiration dates. The Company regularly evaluates the carrying value of its inventory and when, based on such evaluation, factors indicate that impairment has occurred, the Company impairs the inventories’ carrying value. i. Leases Operating leases are included in operating lease right-of-use (“ROU”) assets. Short-term balances regarding lease liabilities are included in accounts payable and accruals - Other and long-term balances regarding lease liabilities are included in operating lease liabilities. ROU assets represent Company’s right to use an underlying asset for the lease term and lease liabilities represent obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. In determining the present value of lease payments, the Company uses the incremental borrowing rate based on the information available at the lease commencement date as the rate implicit in the lease is not readily determinable. The determination of the incremental borrowing rate requires management judgment based on information available at lease commencement. The lease terms may include periods covered by options to extend the lease when it is reasonably certain that the Company will exercise such options, and periods covered by options to terminate the lease when it is reasonably certain that the Company will not exercise such options. Operating lease cost is recognized on a straight-line basis over the lease term. Lease agreements that include lease and non-lease components are accounted for as a single lease component. The Company elected the short-term lease recognition exemption for leases with a lease term of 12 months or less. j. Property, plant and equipment Property, plant and equipment are stated at cost, net of accumulated depreciation and amortization. Depreciation is calculated using the straight-line method over the estimated useful lives of the related assets: over three years for computers and other electronic equipment, and seven to fifteen years for office furniture and equipment and machinery and equipment (mainly seven years). Leasehold improvements are amortized on a straight-line basis over the term of the lease, which is shorter than the estimated life of the improvements. k. Impairment in value of long-lived assets The Company tests long-lived tangible assets for impairment whenever events or circumstances present an indication of impairment. If the sum of expected future cash flows (undiscounted and without interest charges) of the long-lived assets is less than the carrying amount of such assets, an impairment would be recognized, and the assets would be written down to their estimated fair values, based on expected future discounted cash flows. INSPIREMD, INC. NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued) NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES l. Revenue recognition A contract with a customer exists only when: 1) the parties to the contract have approved it and are committed to perform their respective obligations, 2) the Company can identify each party’s rights regarding the distinct goods or services to be transferred (“Performance Obligations”), 3) the Company can determine the transaction price for the goods or services to be transferred, 4) the contract has commercial substance and 5) it is probable that the Company will collect the consideration to which it will be entitled in exchange for the goods or services that will be transferred to the customer. Revenues are recorded in the amount of consideration to which the Company expects to be entitled in exchange for Performance Obligations upon transfer of control to the customer, excluding sales taxes. Revenue from sales of goods, including sales to distributors, is recognized when the customer obtains control of the product, once the Company has a present right to payment and the customer has legal title, and risk and rewards of ownership are obtained by the customer. Generally, this occurs when products are shipped. In few cases when products are directly sold to medical centers on consignment basis, revenue is recognized when the product is consumed. The Company recognizes the incremental costs of obtaining contracts as an expense since the amortization period of the assets that the Company otherwise would have recognized is one year or less. The costs are recorded under selling and marketing expenses. Disaggregated revenue is disclosed in Note 13. The Company recognizes revenue net of value added tax (VAT). m. Research and development costs Research and development costs, including the costs of the Company’s US based clinical trial costs were approximately $ 3,300,000 and $ 4,468,000 for the years ended December 31, 2023 and 2022, respectively, and charged to the statement of operations as incurred. n. Share-based compensation The Company has equity incentive plans under which the Company grants equity awards, including stock options, restricted stock and restricted stock units (“RSUs”) to employees, directors and service providers. Employee and service providers equity awards are accounted for using the grant-date fair value method. The Company determines compensation expense associated with restricted stock and RSUs based on the fair value of our common stock on the date of grant. The fair value of option awards is estimated using the Black-Scholes valuation model and expensed over the requisite service period. The Company elected to account for forfeitures as they occur. The Company elected to recognize compensation expenses for awards to employees with only service conditions that have graded vesting schedules using the accelerated multiple option approach. The attribution for nonemployee awards is in the same manner as if the Company had paid cash for the goods or services. In addition, certain of our share-based awards to service providers are performance based, i.e., the vesting of these awards depends upon achieving certain goals. The company recognizes compensation expenses for awards with performance conditions when the company concludes that it is probable that the performance condition will be achieved. o. Uncertain tax positions The Company follows a two-step approach to recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit. If under the first step a tax position is assessed to be more likely than not of being sustained on audit, the second step is performed, under which the tax benefit is measured as the largest amount that is more than 50% likely to be realized upon ultimate settlement. Such liabilities are classified as long-term, unless the liability is expected to be resolved within twelve months from the balance sheet date. The Company’s policy is to include interest related to unrecognized tax benefits within “Financial expenses - net”. INSPIREMD, INC. NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued) NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES p. Deferred income taxes Deferred taxes are determined utilizing the “asset and liability” method based on the estimated future tax effects of differences between the financial accounting and tax bases of assets and liabilities under the applicable tax laws, and on tax rates anticipated to be in effect when the deferred taxes are expected to be paid or realized. The Company assesses realization of deferred income tax assets and, based on all available evidence, concludes whether it is more likely than not that the net deferred income tax assets will be realized. A valuation allowance is provided for the amount of deferred income tax assets not considered to be realizable. The Company may incur an additional tax liability in the event of intercompany dividend distributions by its subsidiaries. Such additional tax liability in respect of these foreign subsidiaries has not been provided for in these financial statements as it is the Company’s policy to permanently reinvest the subsidiaries’ earnings and to consider distributing dividends only in connection with a specific tax opportunity that may arise. Taxes that would apply in the event of disposal of investments in a foreign subsidiary have not been taken into account in computing the deferred taxes, as it is the Company’s intention to hold, and not to realize, these investments. q. Advertising Costs related to advertising and promotion of products are charged to sales and marketing expense as incurred. Advertising expenses were approximately $ 426,000 and $ 359,000 for the years ended December 31, 2023 and 2022, respectively. r. Net loss per share Basic and diluted net loss per share is computed by dividing the net loss for the period by the weighted average number of shares of common stock, pre-funded warrants and fully vested restricted stock units outstanding during the period. The calculation of diluted net loss per share excludes the effect of potential dilution of share options, warrants, and unvested restricted stocks, unvested restricted stock units and Series C preferred stock as the effect is anti-dilutive. For the purpose of calculating basic net loss per share, the additional shares of common stock that are issuable upon exercise of the Pre-funded Warrants have been included since the shares are issuable for a negligible consideration, as determined by the Company according to ASC 260-10-45-13, and have no vesting or other contingencies associated with them. For the year ended December 31, 2023, we had weighted average Pre-funded Warrants to purchase 9,612,502 share of common stock, which was used in the computation of net loss per share for the year. The total number of shares of common stock related to outstanding options, warrants, unvested restricted stock, unvested restricted stock units and Series C Preferred Stock, which were excluded from the calculations of diluted loss per share were 74,978,006 and 2,741,355 for the years ended December 31, 2023 and 2022, respectively. This amount includes 3,054,086 and 355,951 of unvested restricted stock included in the number of issued and outstanding shares as of December 31, 2023 and 2022, respectively. s. Segment reporting The Company has one operating and reportable segment. t. Fair value measurement The Company measures fair value and discloses fair value measurements for financial assets and liabilities. Fair value is based on the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The accounting standard establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described below: Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs. Level 2: Observable prices that are based on inputs not quoted on active markets but corroborated by market data. Level 3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs. In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible and considers counterparty credit risk in its assessment of fair value. INSPIREMD, INC. NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued) NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES u. Recently adopted accounting pronouncement v. Recently issued accounting pronouncement, not yet adopted 1) In November 2023, the FASB issued ASU 2023-07 “Segment Reporting: Improvements to Reportable Segment Disclosures”. This guidance expands public entities segment disclosures primarily by requiring disclosure of significant segment expenses that are regularly provided to the chief operating decision maker and included within each reported measure of segment profit or loss, an amount and description of its composition for other segment items, and interim disclosures of a reportable segment’s profit or loss and assets. Public entities with a single reportable segment are required to provide the new disclosures and all the disclosures required under ASC 280. The guidance is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. The amendments are required to be applied retrospectively to all prior periods presented in an entity’s financial statements. The Company is currently evaluating this guidance to determine the impact it may have on its consolidated financial statements related disclosures. 2) In December 2023, the FASB issued ASU 2023-09 “Income Taxes (Topic 740): Improvements to Income Tax Disclosures”. This guidance is intended to enhance the transparency and decision-usefulness of income tax disclosures. The amendments in ASU 2023-09 address investor requests for enhanced income tax information primarily through changes to disclosure regarding rate reconciliation and income taxes paid both in the U.S. and in foreign jurisdictions. ASU 2023-09 is effective for fiscal years beginning after December 15, 2024 on a prospective basis, with the option to apply the standard retrospectively. Early adoption is permitted. The Company is currently evaluating this guidance to determine the impact it may have on its consolidated financial statements disclosures. 3) In August 2020, the FASB issued ASU 2020-06 “Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging – Contracts in Entity’s Own Equity (Subtopic 815 – 40).” This guidance simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity’s own equity. This ASU is effective for the Company for fiscal years beginning after December 15, 2023, and interim periods within those fiscal years. The initial adoption of ASU 2020-06 is not expected to have a material impact on the Company’s consolidated financial statements. INSPIREMD, INC. NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

FAIR VALUE MEASUREMENTS

FAIR VALUE MEASUREMENTS	12 Months Ended
	Dec. 31, 2023
Fair Value Disclosures [Abstract]
FAIR VALUE MEASUREMENTS	NOTE 3 – FAIR VALUE MEASUREMENTS As of December 31, 2023, the carrying amounts of accounts payable, accounts receivable and other receivable approximate their fair values due to the short-term maturities of these instruments. The Company’s financial assets subject to fair value measurements on a recurring basis and the level of inputs used in such measurements were as follows: SCHEDULE OF FINANCIAL ASSETS SUBJECT TO FAIR VALUE MEASUREMENTS Total Level 1 Level 2 Level 3 As of December 31, 2023 ($ in thousands) Total Level 1 Level 2 Level 3 Assets: Cash equivalents- Money market funds $ 7,094 $ 7,094 $ - $ - Cash equivalents $ 7,094 $ 7,094 $ - $ - Marketable securities- U.S government bonds $ 29,383 $ - $ 29,383 $ - Marketable securities $ 29,383 $ - $ 29,383 $ - The Company’s debt securities are classified within Level 2 because it uses quoted market prices or alternative pricing sources and models utilizing market observable inputs to determine their fair value. The cost of Marketable securities as of December 31, 2023 is $ 28,727,000

MARKETABLE SECURITIES

MARKETABLE SECURITIES	12 Months Ended
	Dec. 31, 2023
Investments, Debt and Equity Securities [Abstract]
MARKETABLE SECURITIES	NOTE 4 - MARKETABLE SECURITIES The following table sets forth the Company’s marketable securities for the indicated period: SCHEDULE OF MARKETABLE SECURITIES December 31, 2023 ($ in thousands) U.S government bonds $ 29,383 Marketable securities $ 29,383 The following table summarizes the fair value of the Company’s marketable securities classified by maturity as of December 31, 2023: SCHEDULE OF FAIR VALUE OF MARKETABLE SECURITIES CLASSIFIED BY MATURITY December 31, 2023 ($ in thousands) Amounts maturing within one year $ 24,523 Amounts maturing after one year through two years 4,860 $ 29,383 The table below sets forth a summary of the changes in the fair value of the Company’s marketable securities for the year ended December 31, 2023: SCHEDULE OF CHANGES IN FAIR VALUE OF MARKETABLE SECURITIES Year ended 2023 ($ in thousands) Balance at beginning of the period $ - Additions 34,644 Sale or maturity (6,000 ) Interest Received (38 ) Changes in fair value 777 Balance at end of the period 29,383 INSPIREMD, INC. NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

PROPERTY, PLANT AND EQUIPMENT

PROPERTY, PLANT AND EQUIPMENT	12 Months Ended
	Dec. 31, 2023
Property, Plant and Equipment [Abstract]
PROPERTY, PLANT AND EQUIPMENT	NOTE 5 - PROPERTY, PLANT AND EQUIPMENT a. Composition of assets, grouped by major classifications, is as follows: SCHEDULE OF PROPERTY PLANT AND EQUIPMENT 2023 2022 December 31, 2023 2022 ($ in thousands) Cost: Computer equipment $ 425 $ 396 Office furniture and equipment 249 231 Machinery and equipment 1,702 1,704 Leasehold improvements 724 494 Property plant and equipment, gross 3,100 2,825 Less - accumulated depreciation and amortization (2,040 ) (1,908 ) Net carrying amount $ 1,060 $ 917 b. Depreciation and amortization expenses totaled approximately $ 232,000 188,000

LIABILITY FOR EMPLOYEES RIGHT U

LIABILITY FOR EMPLOYEES RIGHT UPON RETIREMENT	12 Months Ended
	Dec. 31, 2023
Retirement Benefits [Abstract]
LIABILITY FOR EMPLOYEES RIGHT UPON RETIREMENT	NOTE 6 - LIABILITY FOR EMPLOYEES RIGHT UPON RETIREMENT Israeli labor law generally requires payment of severance pay upon dismissal of an employee or upon termination of employment in certain other circumstances. Pursuant to section 14 of the Israeli Severance Compensation Act, 1963, most of the Company’s employees are entitled to have monthly deposits, at a rate of 8.33 256,000 241,000 The severance pay liability of the Company for the rest of its Israeli employees, which reflects the undiscounted amount of the liability, is based upon the number of years of service and the latest monthly salary. The severance pay liability is partly covered by insurance policies and by regular deposits with recognized severance payment funds. The Company may only withdraw funds previously deposited for savings in connection with the payment of severance. The severance pay expenses for such employees were approximately $ 116,000 68,000 INSPIREMD, INC. NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

LEASE AGREEMENTS

LEASE AGREEMENTS	12 Months Ended
	Dec. 31, 2023
Lease Agreements
LEASE AGREEMENTS	NOTE 7 – LEASE AGREEMENTS 1) The Company’s Israeli subsidiary had a lease agreement for a facility in Israel, which expired on December 31, 2022 with an option to extend the agreement for two additional years until December 31, 2024. On May 25, 2022 the Company amended the agreement mentioned above and extended it until December 31, 2026 as well as leasing of additional space in the facility. On August 24, 2023, the Company amended the lease agreement mentioned above, leasing additional space in the facility and shortened the lease term of another space in the building. The balances of right of use assets and lease liabilities increased due to the newly leased space and decreased due to the lease that was shortened. 2) Operating lease cost for the years ended December 31, 2023 and 2022 was $ 433,000 442,000 Supplemental information related to leases are as follows: SCHEDULE OF SUPPLEMENTAL INFORMATION RELATED TO LEASES 2023 2022 December 31, 2023 2022 ($ in thousands) Operating lease right-of-use assets 1,473 1,554 Current Operating lease liabilities (557 ) (419 ) Non-current operating lease liabilities (1,038 ) (1,195 ) Other information: Operating cash flows from operating leases (cash paid in thousands) (429 ) (436 ) Weighted Average Remaining Lease Term 3 4 Weighted Average Discount Rate 9.73 % 8.69 % Maturities of lease liabilities are as follows: SCHEDULE OF MATURITIES OF LEASE LIABILITIES Amount ($ in thousands) 2024 579 2025 584 2026 653 Total lease payments 1,816 Less imputed interest (221 ) Total 1,595 INSPIREMD, INC. NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

COMMITMENTS AND CONTINGENT LIAB

COMMITMENTS AND CONTINGENT LIABILITIES	12 Months Ended
	Dec. 31, 2023
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENT LIABILITIES	NOTE 8 - COMMITMENTS AND CONTINGENT LIABILITIES Distribution Agreement with Chinese Partner On February 3, 2021, the Company entered into a distribution agreement (the “Distribution Agreement”) with three China-based partners, pursuant to which the Chinese partners will be responsible for conducting the necessary registration trials for commercial approval of the Company’s products in China, followed by an eight-year exclusive distribution right to sell the Company’s products in China with the term of the agreement continuing on a year-to-year basis unless terminated. Under the Distribution Agreement, the China-based partners will be subject to minimum purchase obligations. The Distribution Agreement may be terminated for cause upon failure to meet minimum purchase obligations, failure to obtain regulatory approvals or for other material breaches. In addition, the agreement stipulates that if the Distributor fails to obtain the Regulatory Approvals by the time stipulated in the agreement due to the failure of the clinical trials, and this Agreement was terminated as a result of such failure to obtain Regulatory Approvals, InspireMD shall reimburse Distributor in an amount which is 50 1,000,000 50

EQUITY

EQUITY	12 Months Ended
	Dec. 31, 2023
Equity [Abstract]
EQUITY	NOTE 9 - EQUITY a. Share capital The Company’s common stock are listed on the Nasdaq Capital Market. Private Placement On May 12, 2023, the Company entered into a securities purchase agreement (the “Purchase Agreement”) pursuant to which the Company agreed to sell and issue in a private placement (the “Private Placement Offering) an aggregate of 10,266,270 15,561,894 51,656,328 12,914,086 12,914,078 12,914,086 12,914,078 1.6327 1.6326 Aggregate gross proceeds to the Company in respect of the Private Placement Offering were $ 42.2 4.6 71.4 INSPIREMD, INC. NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued) NOTE 9 – EQUITY The Pre-Funded Warrants are immediately exercisable at an exercise price of $ 0.0001 1.3827 The Company issued a total of 307,260 307,271 15,254,623 Pursuant to the full ratchet anti-dilution adjustment provisions in the respective certificate of designation for the Company’s Series C Preferred Stock, the conversion price of the outstanding shares of the Series C Preferred Stock was reduced to $ 1.3827 5,668 1,718 As of December 31, 2023 and 2022, there were 1,718 7,952 2,284 10,997 As of December 31, 2023, the Company has outstanding warrants to purchase an aggregate of 53,396,008 SCHEDULE OF ISSUANCE OF WARRANTS TO PURCHASE COMMON STOCK Number of underlying Common stock Exercise price Series E Warrants 198,159 $ 27.0000 Series F Warrants 433,878 $ 7.4250 Series G Warrants 1,092,344 $ 10.2300 Series H Warrants 12,914,086 $ 1.3827 Series I Warrants 12,914,078 $ 1.3827 Series J Warrants 12,914,086 $ 1.3827 Series K Warrants 12,914,078 $ 1.3827 Underwriter Warrants 15,299 $ 7.4250 Total Warrants 53,396,008 $ As of December 31, 2023, the Company has 155,000,000 0.0001 150,000,000 5,000,000 INSPIREMD, INC. NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued) NOTE 9 – EQUITY b. Share-Based Compensation 1) On September 30, 2021, at our 2021 annual meeting of stockholders, our stockholders approved our 2021 Equity Incentive Plan. The Company’s. 2021 Equity Incentive Plan provides for the granting of incentive stock options, nonqualified stock options, stock appreciation rights, restricted stock, restricted stock units, performance awards, dividend equivalent rights, and other awards, which may be granted singly, in combination, or in tandem. As of December 31, 2023, we had 7,731,618 5) The following table summarizes information about stock options granted to employees: SCHEDULE OF STOCK OPTIONS GRANTED Year ended December 31 2023 2022 Number of options Weighted average exercise price Number of options Weighted average exercise price Outstanding - beginning of period 294,712 5.21 289,408 $ 5.29 Granted 1,097,250 1.89 7,841 2.61 Forfeited (12,266 ) 4.00 (2,537 ) 5.70 Outstanding- end of period 1,379,696 2.58 294,712 $ 5.21 Exercisable at the end of the period 215,709 5.38 123,115 5.51 6) The following table summarizes information about stock options granted to non-employees: Year ended December 31 2023 2022 Number of options Weighted average exercise price Number of options Weighted average exercise price Outstanding - beginning of period 166,669 3.37 20,002 6.90 Granted 625,000 1.71 146,667 2.89 Outstanding - end of period 791,669 2.06 166,669 3.37 Exercisable at the end of the period 84,667 3.42 35,667 3.61 7) The following table summarizes information about restricted stock granted to employees: SCHEDULE OF RESTRICTED STOCK GRANTED TO EMPLOYEES Year ended December 31 2023 2022 Number of restricted stock Outstanding - beginning of period 355,951 527,668 Granted 2,914,340 45,494 Forfeited (29,695 ) (10,832 ) Vested (186,510 ) (206,379 ) Outstanding - end of period 3,054,086 355,951 INSPIREMD, INC. NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued) NOTE 9 – EQUITY 8) The following table summarizes information about RSUs granted to employees: SCHEDULE OF RESTRICTED STOCK UNIT GRANTED TO EMPLOYEES Year ended December 31 2023 2022 Number of RSUs Outstanding - beginning of period 237,078 237,078 Granted 1,045,150 - Outstanding - end of period 1,282,228 237,078 9) The following table provides additional information about all options outstanding and exercisable: SCHEDULE OF ADDITIONAL INFORMATION ABOUT ALL OPTIONS OUTSTANDING AND EXERCISABLE Outstanding as of December 31, 2023 Exercise price Options outstanding Weighted average remaining contractual life (years) Options exercisable $ 1.15 2.97 1,786,211 9.28 73,946 $ 3.30 4.12 227,932 8.53 95,075 $ 4.95 10.05 153,169 7.00 127,303 $ 16.50 4,053 6.01 4,053 2,171,365 9.03 300,376 The weighted average of the remaining contractual life of total vested and exercisable options as of December 31, 2023 was 7.54 The aggregate intrinsic value of the total exercisable options as of December 31, 2023 was approximately $ 10,983 The weighted average fair value of options granted to employees was $ 1.65 2.33 The weighted average fair value of options granted to consultants was $ 1.50 2.57 The weighted average fair value of restricted stock granted was $ 1.95 2.42 The weighted average fair value of RSU granted was $ 1.76 The vesting period for outstanding stock options, restricted stock, and RSUs is typically three years, with one-third of the awards vesting annually. Additionally, some of our share-based awards to service providers are performance-based, vesting upon the achievement of specified performance criteria related to clinical or marketing activities. INSPIREMD, INC. NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued) NOTE 9 – EQUITY 10) The following table sets forth the assumptions that were used in determining the fair value of options granted to employees for the year December 31, 2023 and 2022: SCHEDULE OF FAIR VALUE OF OPTIONS GRANTED TO EMPLOYEES Year ended December 31 2023 2022 Expected life 5.125 6.5 5.125 6.5 Risk-free interest rates 3.58 4.73 1.79 2.88 Volatility 109.62 125.61 127.43 130.93 Dividend yield - - The Company does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate expected term. Accordingly, as to ordinary course options granted, the expected term was determined using the simplified method, which takes into consideration the option’s contractual life and the vesting periods (for non-employees, the expected term is equal to the option’s contractual life). The annual risk-free rates are based on the yield rates of zero coupon non-index linked U.S. Federal Reserve treasury bonds as both the exercise price and the share price are in dollar terms. The Company’s expected volatility is derived from its historical data. 11) As of December 31, 2023, the total unrecognized compensation cost on employee and non-employee stock options, restricted stock and RSUs, related to unvested stock-based compensation, amounted to approximately $ 7.18 0.97 12) The following table summarizes the allocation of total share-based compensation expense in the consolidated statements of operations: SCHEDULE OF ALLOCATION OF TOTAL SHARE-BASED COMPENSATION EXPENSE Year ended December 31 2023 2022 ($ in thousands) Cost of revenues $ 93 $ 72 Research and development 649 582 Sales and marketing 416 318 General and administrative 3,332 1,380 $ 4,490 $ 2,352 INSPIREMD, INC. NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

RELATED PARTIES TRANSACTIONS

RELATED PARTIES TRANSACTIONS	12 Months Ended
	Dec. 31, 2023
Related Party Transactions [Abstract]
RELATED PARTIES TRANSACTIONS	NOTE 10 – RELATED PARTIES TRANSACTIONS 1) During the twelve months ended December 31, 2023 and 2022, a consulting company whose founder and CEO is our board member provided certain marketing services in the amount of $ 788 9,645 2) On September 15, 2023, the board approved the company’s entry into a consultancy agreement with a member of the immediate family of the CEO for certain administrative projects in connection with the Company’s expansion to the U.S. until a full-time Company employee is retained in such capacity. Pursuant to the Consultancy Agreement, the Company will pay a fixed hourly fee of $ 50 Consulting expenses for the year ended December 31, 2023, were $ 11,440 3) Election to Receive Shares of Common Stock in lieu of Cash Compensation For the year 2023, certain non-employee directors elected to receive all or a portion of their cash retainer amount in shares of the Company’s common stock under the 2021 Equity Incentive Plan. For a director that made that election, a stock award under the 2021 Equity Incentive Plan was paid quarterly on the first day of each next quarter (“Issuance Dates”) and became fully vested on the Issuance Dates. The stock award was determined by dividing (x) the product of the cash retainer amount and percentage of the cash retainer amount elected to be taken in shares by (y) the “Fair Market Value” (as defined in the 2021 Equity Incentive Plan) of a share on the Issuance Dates. During the years ended December 31, 2023 the Company issued 52,129 As of December 31, 2023, there was an accrual for $ 55,000 22,875 32,125 11,854

TAXES ON INCOME_

TAXES ON INCOME:	12 Months Ended
	Dec. 31, 2023
Income Tax Disclosure [Abstract]
TAXES ON INCOME:	NOTE 11 - TAXES ON INCOME: a. Tax laws applicable to the Company and its subsidiaries Taxation in the United States InspireMD, Inc. is taxed under U.S. tax laws. Accordingly, the applicable federal corporate tax rate in 2023 is 21 Taxation in Israel InspiredMD, Ltd is taxed under Israeli tax laws. Accordingly, the applicable corporate tax rate in 2023 is 23 Taxation in Germany InspireMD GmbH is taxed according to the tax laws in Germany. Accordingly, the applicable tax rates are corporate tax rate of 15.825 17.15 INSPIREMD, INC. NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued) NOTE 11 - TAXES ON INCOME: b. Tax benefits under the Law for the Encouragement of Capital Investments, 1959 (the “Law”): On December 29, 2016, the Investment Law was amended (“73 Amendment”), which includes, inter alia, two new tax incentive opportunities. These are the Preferred Technological Enterprise (“PTE”) and Special Preferred Technological Enterprise (“SPTE”). In order to benefit from either of these options, a Company must meet certain qualifications and receive formal approval from the Israel Innovation Authority (“IIA”) which allows the Company to use the reduced corporate tax rate of 12 6 Furthermore, according to the provisions regarding “preferred technology enterprise” and “special preferred technology enterprise” in the Law and the regulations thereunder, and to the extent the income is attributable to manufacturing, this income is classified as “preferred income” and is taxed at 7.5 16 Additionally, when income of a company originating from “preferred technology income” is distributed as dividend to a foreign-resident corporation, tax withholding from the dividend is 4 90 c. Carry forward tax losses As of December 31, 2023, the Company had a net carry forward tax loss of approximately $ 54 35 expires until 2038 19 80 Under the U.S. tax laws, for net operating losses (NOLs) arising after December 31, 2017, the Tax Cuts and Jobs Act enacted on December 22, 2017 (the “2017 Act”) limits a taxpayer’s ability to utilize NOL carryforwards to 80% of taxable income. In addition, NOLs arising after 2017 can be carried forward indefinitely, but carryback is generally prohibited. NOLs generated in tax years beginning before January 1, 2018, will not be subject to the foregoing taxable income limitation and will continue to have a two-year carryback and twenty-year carryforward period. As of December 31, 2023, InspireMD Ltd., an Israeli subsidiary, had a net carry forward tax loss of approximately $ 107 The Israeli subsidiary is taxed in the New Israeli Shekel (“NIS”), which is different from its functional currency (U.S. Dollar). The change in the Israeli subsidiary NOL’s for tax purposes is partly resulted by such rate differences. d. Loss before income taxes The components of loss before income taxes are as follows: SCHEDULE OF COMPONENTS OF LOSS BEFORE INCOME TAXES Year ended December 31 2023 2022 ($ in thousands) Loss before taxes on income: InspireMD, Inc. $ (5,772 ) $ (4,773 ) Subsidiaries (14,079 ) (13,690 ) $ (19,851 ) $ (18,463 ) INSPIREMD, INC. NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued) NOTE 11 - TAXES ON INCOME e. Current taxes on income The main reconciling item between the statutory tax rate of the Company and the effective tax rate is the change in valuation allowance in respect of tax benefits from carried forward tax losses due to uncertainty of the realization of such tax benefits. The changes in the valuation allowance for the year ended December 31, 2023 and 2022 were as follows: SCHEDULE OF CHANGES IN VALUATION ALLOWANCE Year ended December 31 2023 2022 ($ in thousands) Balance at the beginning of the year $ 40,071 $ 39,212 Changes during the year: Losses during the year (including foreign exchange rate effect) 2,580 859 Balance at the end of the year $ 42,651 $ 40,071 f. Accounting for Uncertain Tax position The following is a reconciliation of the total amounts of the Company’s uncertain tax positions during the year ended December 31, 2023 and 2022 were as follows: SCHEDULE OF RECONCILIATION OF UNCERTAIN TAX POSITIONS Year ended December 31, 2023 2022 ($ in thousands) Balance at beginning of period $ 106 $ 89 Increase in uncertain tax positions because of tax positions taken during the year 62 17 Balance at end of period $ 168 $ 106 A summary of open tax years by major jurisdiction is presented below: SCHEDULE OF OPEN TAX YEARS BY MAJOR JURISDICTION Jurisdiction Years U.S. 2020 2023 Israel 2019 2023 Germany 2020 2023 g. Deferred income tax: SCHEDULE OF DEFERRED INCOME TAX 2023 2022 December 31, 2023 2022 ($ in thousands) Provision for vacation and recreation pay 68 45 R&D expenses 1,691 1,452 Operating lease right of use assets (339 ) (357 ) Operating lease liabilities 367 371 Share-based compensation 3,492 3,021 Carry forward tax losses 37,342 35,507 Accrued severance pay, net 30 32 Deferred tax assets noncurrent 42,651 40,071 Less-valuation allowance (42,651 ) (40,071 ) Deferred tax assets - - INSPIREMD, INC. NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

SUPPLEMENTARY FINANCIAL STATEME

SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION	12 Months Ended
	Dec. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION	NOTE 12 - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION Balance sheets: Inventory: SCHEDULE OF INVENTORIES 2023 2022 December 31, 2023 2022 ($ in thousands) Finished goods $ 210 $ 179 Work in process 562 510 Raw materials and supplies 1,334 932 Total inventory $ 2,106 $ 1,621 SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUALS - OTHER a. Accounts payable and accruals-other: 2023 2022 December 31, 2023 2022 ($ in thousands) Employees and employee institutions $ 2,188 $ 1,853 Accrued vacation and recreation pay 287 197 Accrued expenses 1,115 554 Clinical trial accrual 744 1,258 Current Operating lease liabilities 557 419 Other 190 130 Accounts Payable and Accruals - Other $ 5,081 $ 4,411

DISAGGREGATED REVENUE AND ENTIT

DISAGGREGATED REVENUE AND ENTITY WIDE DISCLOSURES	12 Months Ended
	Dec. 31, 2023
Segment Reporting [Abstract]
DISAGGREGATED REVENUE AND ENTITY WIDE DISCLOSURES	NOTE 13 – DISAGGREGATED REVENUE AND ENTITY WIDE DISCLOSURES Revenues are attributed to geographic areas based on the location of the customers. The following is a summary of revenues: SCHEDULE OF REVENUES ATTRIBUTED TO GEOGRAPHIC AREAS Year ended December 31, 2023 2022 ($ in thousands) Italy $ 1,195 $ 970 Germany 896 866 Russia 738 381 Other 3,376 2,954 $ 6,205 $ 5,171 By product: SCHEDULE OF REVENUES ATTRIBUTED TO GEOGRAPHIC AREAS BY PRODUCT Year ended December 31, 2023 2022 ($ in thousands) CGuard™ EPS $ 6,205 $ 5,123 MGuard Prime™ EPS - 48 $ 6,205 $ 5,171 By principal customers: SCHEDULE OF REVENUES ATTRIBUTED TO GEOGRAPHIC AREAS BY PRINCIPAL CUSTOMERS Year ended December 31, 2023 2022 Customer A 14 % 17 % Customer B 12 % 7 % All tangible long lived assets are located in Israel.

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	12 Months Ended
	Dec. 31, 2023
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 14 - SUBSEQUENT EVENTS On January 23, 2024, the Company granted 1,528,316 restricted shares of the Company’s common stock to employees and directors. The shares to employees are subject to a three-year vesting period, with one-third of such awards vesting each year. The shares to directors are subject to a one-year vesting period. On January 23, 2024, the Company granted 563,499 restricted share units of the Company’s common stock to the chief executive officer. The shares are subject to a three-year vesting period, with one-third of such awards vesting each year. On January 23, 2024, the Company granted to employees and directors options to purchase a total of 669,464 shares of the Company’s common stock. The options have an exercise prices of $3.14 per share, which was the fair market value of the Company’s common stock on the date of the grant. The options to employees are subject to a three-year vesting period, with one-third of such awards vesting each year. The options to directors are subject to a one-year vesting period.

SIGNIFICANT ACCOUNTING POLICI_2

SIGNIFICANT ACCOUNTING POLICIES (Policies)	12 Months Ended
	Dec. 31, 2023
Accounting Policies [Abstract]
Use of estimates	a. Use of estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates using assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates. As applicable to these consolidated financial statements, the most significant estimates and assumptions relate to inventory valuations and assessing the likelihood of exercise of options to extend the lease term.
Functional currency	b. Functional currency The currency of the primary economic environment in which the operations of the Company and its subsidiaries are conducted is the U.S. dollar (“$” or “dollar”). Accordingly, the functional currency of the Company and its subsidiaries is the U.S. dollar. The dollar figures are determined as follows: transactions and balances originally denominated in dollars are presented in their original amounts. Balances in foreign currencies are translated into dollars using historical and current exchange rates for non-monetary and monetary balances, respectively. The resulting translation gains or losses are recorded as financial income or expense, as appropriate. For transactions reflected in the statements of operations in foreign currencies, the exchange rates at transaction dates are used. Depreciation and changes in inventories and other changes deriving from non-monetary items are based on historical exchange rates.
Principles of consolidation	c. Principles of consolidation The consolidated financial statements include the accounts of the Company and of its subsidiaries. Intercompany transactions and balances have been eliminated upon consolidation.
Cash and cash equivalents	d. Cash and cash equivalents The Company considers all highly liquid investments purchased with original maturities of three months or less from the purchase date to be cash equivalents. As of December 31, 2023, cash and cash equivalents consisted of cash, short-term deposits (up to three months from the date of deposit) and money market funds. As of December 31, 2022, this balance consisted solely of cash.
Marketable securities	e. Marketable securities Marketable securities consist of debt securities. The Company elected the fair value option to measure and recognize its investments in debt securities in accordance with ASC 825, Financial Instruments as the Company manages its portfolio and evaluates the performance on a fair value basis. Changes in fair value, realized gains and losses on sales of marketable securities, are reflected in the statements of operation as finance expense (income), net. Marketable securities are classified under current assets in the consolidated balance sheet as they represent the investment of funds available for the Company’s current operations. INSPIREMD, INC. NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued) NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES
Short-term bank deposits	f. Short-term bank deposits Bank deposits with original maturities of more than three months but less than one year are presented as part of short-term bank deposits. Deposits are presented at their cost which approximates market values including accrued interest. Interest on deposits is recorded as financial income.
Concentration of credit risk and allowance for doubtful accounts	g. Concentration of credit risk and allowance for doubtful accounts Financial instruments that may potentially subject the Company to a concentration of credit risk consist of cash and cash equivalents and short-term bank deposits, which are deposited in major financially sound institutions in the U.S, Israel and Germany, and trade accounts receivable and other receivables. The Company’s trade accounts receivable is derived from revenues earned from customers from various countries. The Company performs ongoing credit evaluations of its customers’ financial condition and, requires no collateral from its customers. The Company also has a credit insurance policy for some of its customers. The Company maintains the allowance for estimated losses resulting from the inability of the Company’s customers to make required payments. The allowance represents the current estimate of lifetime expected credit losses over the remaining duration of existing accounts receivable considering current market conditions and supportable forecasts when appropriate. The estimate is a result of the Company’s ongoing evaluation of collectability, customer creditworthiness, historical levels of credit losses, and future expectations. The allowance for expected credit losses was immaterial during the periods presented.
Inventory	h. Inventory Inventories are stated at the lower of cost (cost is determined on a “first-in, first-out” basis) or net realizable value. The Company’s inventories generally have a limited shelf life and are subject to impairment as they approach their expiration dates. The Company regularly evaluates the carrying value of its inventory and when, based on such evaluation, factors indicate that impairment has occurred, the Company impairs the inventories’ carrying value.
Leases	i. Leases Operating leases are included in operating lease right-of-use (“ROU”) assets. Short-term balances regarding lease liabilities are included in accounts payable and accruals - Other and long-term balances regarding lease liabilities are included in operating lease liabilities. ROU assets represent Company’s right to use an underlying asset for the lease term and lease liabilities represent obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. In determining the present value of lease payments, the Company uses the incremental borrowing rate based on the information available at the lease commencement date as the rate implicit in the lease is not readily determinable. The determination of the incremental borrowing rate requires management judgment based on information available at lease commencement. The lease terms may include periods covered by options to extend the lease when it is reasonably certain that the Company will exercise such options, and periods covered by options to terminate the lease when it is reasonably certain that the Company will not exercise such options. Operating lease cost is recognized on a straight-line basis over the lease term. Lease agreements that include lease and non-lease components are accounted for as a single lease component. The Company elected the short-term lease recognition exemption for leases with a lease term of 12 months or less.
Property, plant and equipment	j. Property, plant and equipment Property, plant and equipment are stated at cost, net of accumulated depreciation and amortization. Depreciation is calculated using the straight-line method over the estimated useful lives of the related assets: over three years for computers and other electronic equipment, and seven to fifteen years for office furniture and equipment and machinery and equipment (mainly seven years). Leasehold improvements are amortized on a straight-line basis over the term of the lease, which is shorter than the estimated life of the improvements.
Impairment in value of long-lived assets	k. Impairment in value of long-lived assets The Company tests long-lived tangible assets for impairment whenever events or circumstances present an indication of impairment. If the sum of expected future cash flows (undiscounted and without interest charges) of the long-lived assets is less than the carrying amount of such assets, an impairment would be recognized, and the assets would be written down to their estimated fair values, based on expected future discounted cash flows. INSPIREMD, INC. NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued) NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES
Revenue recognition	l. Revenue recognition A contract with a customer exists only when: 1) the parties to the contract have approved it and are committed to perform their respective obligations, 2) the Company can identify each party’s rights regarding the distinct goods or services to be transferred (“Performance Obligations”), 3) the Company can determine the transaction price for the goods or services to be transferred, 4) the contract has commercial substance and 5) it is probable that the Company will collect the consideration to which it will be entitled in exchange for the goods or services that will be transferred to the customer. Revenues are recorded in the amount of consideration to which the Company expects to be entitled in exchange for Performance Obligations upon transfer of control to the customer, excluding sales taxes. Revenue from sales of goods, including sales to distributors, is recognized when the customer obtains control of the product, once the Company has a present right to payment and the customer has legal title, and risk and rewards of ownership are obtained by the customer. Generally, this occurs when products are shipped. In few cases when products are directly sold to medical centers on consignment basis, revenue is recognized when the product is consumed. The Company recognizes the incremental costs of obtaining contracts as an expense since the amortization period of the assets that the Company otherwise would have recognized is one year or less. The costs are recorded under selling and marketing expenses. Disaggregated revenue is disclosed in Note 13. The Company recognizes revenue net of value added tax (VAT).
Research and development costs	m. Research and development costs Research and development costs, including the costs of the Company’s US based clinical trial costs were approximately $ 3,300,000 and $ 4,468,000 for the years ended December 31, 2023 and 2022, respectively, and charged to the statement of operations as incurred.
Share-based compensation	n. Share-based compensation The Company has equity incentive plans under which the Company grants equity awards, including stock options, restricted stock and restricted stock units (“RSUs”) to employees, directors and service providers. Employee and service providers equity awards are accounted for using the grant-date fair value method. The Company determines compensation expense associated with restricted stock and RSUs based on the fair value of our common stock on the date of grant. The fair value of option awards is estimated using the Black-Scholes valuation model and expensed over the requisite service period. The Company elected to account for forfeitures as they occur. The Company elected to recognize compensation expenses for awards to employees with only service conditions that have graded vesting schedules using the accelerated multiple option approach. The attribution for nonemployee awards is in the same manner as if the Company had paid cash for the goods or services. In addition, certain of our share-based awards to service providers are performance based, i.e., the vesting of these awards depends upon achieving certain goals. The company recognizes compensation expenses for awards with performance conditions when the company concludes that it is probable that the performance condition will be achieved.
Deferred income taxes	o. Uncertain tax positions The Company follows a two-step approach to recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit. If under the first step a tax position is assessed to be more likely than not of being sustained on audit, the second step is performed, under which the tax benefit is measured as the largest amount that is more than 50% likely to be realized upon ultimate settlement. Such liabilities are classified as long-term, unless the liability is expected to be resolved within twelve months from the balance sheet date. The Company’s policy is to include interest related to unrecognized tax benefits within “Financial expenses - net”. INSPIREMD, INC. NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued) NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES p. Deferred income taxes Deferred taxes are determined utilizing the “asset and liability” method based on the estimated future tax effects of differences between the financial accounting and tax bases of assets and liabilities under the applicable tax laws, and on tax rates anticipated to be in effect when the deferred taxes are expected to be paid or realized. The Company assesses realization of deferred income tax assets and, based on all available evidence, concludes whether it is more likely than not that the net deferred income tax assets will be realized. A valuation allowance is provided for the amount of deferred income tax assets not considered to be realizable. The Company may incur an additional tax liability in the event of intercompany dividend distributions by its subsidiaries. Such additional tax liability in respect of these foreign subsidiaries has not been provided for in these financial statements as it is the Company’s policy to permanently reinvest the subsidiaries’ earnings and to consider distributing dividends only in connection with a specific tax opportunity that may arise. Taxes that would apply in the event of disposal of investments in a foreign subsidiary have not been taken into account in computing the deferred taxes, as it is the Company’s intention to hold, and not to realize, these investments.
Advertising	q. Advertising Costs related to advertising and promotion of products are charged to sales and marketing expense as incurred. Advertising expenses were approximately $ 426,000 and $ 359,000 for the years ended December 31, 2023 and 2022, respectively.
Net loss per share	r. Net loss per share Basic and diluted net loss per share is computed by dividing the net loss for the period by the weighted average number of shares of common stock, pre-funded warrants and fully vested restricted stock units outstanding during the period. The calculation of diluted net loss per share excludes the effect of potential dilution of share options, warrants, and unvested restricted stocks, unvested restricted stock units and Series C preferred stock as the effect is anti-dilutive. For the purpose of calculating basic net loss per share, the additional shares of common stock that are issuable upon exercise of the Pre-funded Warrants have been included since the shares are issuable for a negligible consideration, as determined by the Company according to ASC 260-10-45-13, and have no vesting or other contingencies associated with them. For the year ended December 31, 2023, we had weighted average Pre-funded Warrants to purchase 9,612,502 share of common stock, which was used in the computation of net loss per share for the year. The total number of shares of common stock related to outstanding options, warrants, unvested restricted stock, unvested restricted stock units and Series C Preferred Stock, which were excluded from the calculations of diluted loss per share were 74,978,006 and 2,741,355 for the years ended December 31, 2023 and 2022, respectively. This amount includes 3,054,086 and 355,951 of unvested restricted stock included in the number of issued and outstanding shares as of December 31, 2023 and 2022, respectively.
Segment reporting	s. Segment reporting The Company has one operating and reportable segment.
Fair value measurement	t. Fair value measurement The Company measures fair value and discloses fair value measurements for financial assets and liabilities. Fair value is based on the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The accounting standard establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described below: Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs. Level 2: Observable prices that are based on inputs not quoted on active markets but corroborated by market data. Level 3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs. In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible and considers counterparty credit risk in its assessment of fair value. INSPIREMD, INC. NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued) NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES
Recently adopted accounting pronouncement	u. Recently adopted accounting pronouncement
Recently issued accounting pronouncement, not yet adopted	v. Recently issued accounting pronouncement, not yet adopted 1) In November 2023, the FASB issued ASU 2023-07 “Segment Reporting: Improvements to Reportable Segment Disclosures”. This guidance expands public entities segment disclosures primarily by requiring disclosure of significant segment expenses that are regularly provided to the chief operating decision maker and included within each reported measure of segment profit or loss, an amount and description of its composition for other segment items, and interim disclosures of a reportable segment’s profit or loss and assets. Public entities with a single reportable segment are required to provide the new disclosures and all the disclosures required under ASC 280. The guidance is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. The amendments are required to be applied retrospectively to all prior periods presented in an entity’s financial statements. The Company is currently evaluating this guidance to determine the impact it may have on its consolidated financial statements related disclosures. 2) In December 2023, the FASB issued ASU 2023-09 “Income Taxes (Topic 740): Improvements to Income Tax Disclosures”. This guidance is intended to enhance the transparency and decision-usefulness of income tax disclosures. The amendments in ASU 2023-09 address investor requests for enhanced income tax information primarily through changes to disclosure regarding rate reconciliation and income taxes paid both in the U.S. and in foreign jurisdictions. ASU 2023-09 is effective for fiscal years beginning after December 15, 2024 on a prospective basis, with the option to apply the standard retrospectively. Early adoption is permitted. The Company is currently evaluating this guidance to determine the impact it may have on its consolidated financial statements disclosures. 3) In August 2020, the FASB issued ASU 2020-06 “Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging – Contracts in Entity’s Own Equity (Subtopic 815 – 40).” This guidance simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity’s own equity. This ASU is effective for the Company for fiscal years beginning after December 15, 2023, and interim periods within those fiscal years. The initial adoption of ASU 2020-06 is not expected to have a material impact on the Company’s consolidated financial statements.

FAIR VALUE MEASUREMENTS (Tables

FAIR VALUE MEASUREMENTS (Tables)	12 Months Ended
	Dec. 31, 2023
Fair Value Disclosures [Abstract]
SCHEDULE OF FINANCIAL ASSETS SUBJECT TO FAIR VALUE MEASUREMENTS	The Company’s financial assets subject to fair value measurements on a recurring basis and the level of inputs used in such measurements were as follows: SCHEDULE OF FINANCIAL ASSETS SUBJECT TO FAIR VALUE MEASUREMENTS Total Level 1 Level 2 Level 3 As of December 31, 2023 ($ in thousands) Total Level 1 Level 2 Level 3 Assets: Cash equivalents- Money market funds $ 7,094 $ 7,094 $ - $ - Cash equivalents $ 7,094 $ 7,094 $ - $ - Marketable securities- U.S government bonds $ 29,383 $ - $ 29,383 $ - Marketable securities $ 29,383 $ - $ 29,383 $ -

MARKETABLE SECURITIES (Tables)

MARKETABLE SECURITIES (Tables)	12 Months Ended
	Dec. 31, 2023
Investments, Debt and Equity Securities [Abstract]
SCHEDULE OF MARKETABLE SECURITIES	The following table sets forth the Company’s marketable securities for the indicated period: SCHEDULE OF MARKETABLE SECURITIES December 31, 2023 ($ in thousands) U.S government bonds $ 29,383 Marketable securities $ 29,383
SCHEDULE OF FAIR VALUE OF MARKETABLE SECURITIES CLASSIFIED BY MATURITY	The following table summarizes the fair value of the Company’s marketable securities classified by maturity as of December 31, 2023: SCHEDULE OF FAIR VALUE OF MARKETABLE SECURITIES CLASSIFIED BY MATURITY December 31, 2023 ($ in thousands) Amounts maturing within one year $ 24,523 Amounts maturing after one year through two years 4,860 $ 29,383
SCHEDULE OF CHANGES IN FAIR VALUE OF MARKETABLE SECURITIES	The table below sets forth a summary of the changes in the fair value of the Company’s marketable securities for the year ended December 31, 2023: SCHEDULE OF CHANGES IN FAIR VALUE OF MARKETABLE SECURITIES Year ended 2023 ($ in thousands) Balance at beginning of the period $ - Additions 34,644 Sale or maturity (6,000 ) Interest Received (38 ) Changes in fair value 777 Balance at end of the period 29,383 INSPIREMD, INC. NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

PROPERTY, PLANT AND EQUIPMENT (

PROPERTY, PLANT AND EQUIPMENT (Tables)	12 Months Ended
	Dec. 31, 2023
Property, Plant and Equipment [Abstract]
SCHEDULE OF PROPERTY PLANT AND EQUIPMENT	SCHEDULE OF PROPERTY PLANT AND EQUIPMENT 2023 2022 December 31, 2023 2022 ($ in thousands) Cost: Computer equipment $ 425 $ 396 Office furniture and equipment 249 231 Machinery and equipment 1,702 1,704 Leasehold improvements 724 494 Property plant and equipment, gross 3,100 2,825 Less - accumulated depreciation and amortization (2,040 ) (1,908 ) Net carrying amount $ 1,060 $ 917 b. Depreciation and amortization expenses totaled approximately $ 232,000 188,000

LEASE AGREEMENTS (Tables)

LEASE AGREEMENTS (Tables)	12 Months Ended
	Dec. 31, 2023
Lease Agreements
SCHEDULE OF SUPPLEMENTAL INFORMATION RELATED TO LEASES	Supplemental information related to leases are as follows: SCHEDULE OF SUPPLEMENTAL INFORMATION RELATED TO LEASES 2023 2022 December 31, 2023 2022 ($ in thousands) Operating lease right-of-use assets 1,473 1,554 Current Operating lease liabilities (557 ) (419 ) Non-current operating lease liabilities (1,038 ) (1,195 ) Other information: Operating cash flows from operating leases (cash paid in thousands) (429 ) (436 ) Weighted Average Remaining Lease Term 3 4 Weighted Average Discount Rate 9.73 % 8.69 %
SCHEDULE OF MATURITIES OF LEASE LIABILITIES	Maturities of lease liabilities are as follows: SCHEDULE OF MATURITIES OF LEASE LIABILITIES Amount ($ in thousands) 2024 579 2025 584 2026 653 Total lease payments 1,816 Less imputed interest (221 ) Total 1,595

EQUITY (Tables)

EQUITY (Tables)	12 Months Ended
	Dec. 31, 2023
Equity [Abstract]
SCHEDULE OF ISSUANCE OF WARRANTS TO PURCHASE COMMON STOCK	SCHEDULE OF ISSUANCE OF WARRANTS TO PURCHASE COMMON STOCK Number of underlying Common stock Exercise price Series E Warrants 198,159 $ 27.0000 Series F Warrants 433,878 $ 7.4250 Series G Warrants 1,092,344 $ 10.2300 Series H Warrants 12,914,086 $ 1.3827 Series I Warrants 12,914,078 $ 1.3827 Series J Warrants 12,914,086 $ 1.3827 Series K Warrants 12,914,078 $ 1.3827 Underwriter Warrants 15,299 $ 7.4250 Total Warrants 53,396,008 $
SCHEDULE OF STOCK OPTIONS GRANTED	SCHEDULE OF STOCK OPTIONS GRANTED Year ended December 31 2023 2022 Number of options Weighted average exercise price Number of options Weighted average exercise price Outstanding - beginning of period 294,712 5.21 289,408 $ 5.29 Granted 1,097,250 1.89 7,841 2.61 Forfeited (12,266 ) 4.00 (2,537 ) 5.70 Outstanding- end of period 1,379,696 2.58 294,712 $ 5.21 Exercisable at the end of the period 215,709 5.38 123,115 5.51 6) The following table summarizes information about stock options granted to non-employees: Year ended December 31 2023 2022 Number of options Weighted average exercise price Number of options Weighted average exercise price Outstanding - beginning of period 166,669 3.37 20,002 6.90 Granted 625,000 1.71 146,667 2.89 Outstanding - end of period 791,669 2.06 166,669 3.37 Exercisable at the end of the period 84,667 3.42 35,667 3.61
SCHEDULE OF RESTRICTED STOCK GRANTED TO EMPLOYEES	SCHEDULE OF RESTRICTED STOCK GRANTED TO EMPLOYEES Year ended December 31 2023 2022 Number of restricted stock Outstanding - beginning of period 355,951 527,668 Granted 2,914,340 45,494 Forfeited (29,695 ) (10,832 ) Vested (186,510 ) (206,379 ) Outstanding - end of period 3,054,086 355,951
SCHEDULE OF RESTRICTED STOCK UNIT GRANTED TO EMPLOYEES	SCHEDULE OF RESTRICTED STOCK UNIT GRANTED TO EMPLOYEES Year ended December 31 2023 2022 Number of RSUs Outstanding - beginning of period 237,078 237,078 Granted 1,045,150 - Outstanding - end of period 1,282,228 237,078
SCHEDULE OF ADDITIONAL INFORMATION ABOUT ALL OPTIONS OUTSTANDING AND EXERCISABLE	SCHEDULE OF ADDITIONAL INFORMATION ABOUT ALL OPTIONS OUTSTANDING AND EXERCISABLE Outstanding as of December 31, 2023 Exercise price Options outstanding Weighted average remaining contractual life (years) Options exercisable $ 1.15 2.97 1,786,211 9.28 73,946 $ 3.30 4.12 227,932 8.53 95,075 $ 4.95 10.05 153,169 7.00 127,303 $ 16.50 4,053 6.01 4,053 2,171,365 9.03 300,376
SCHEDULE OF FAIR VALUE OF OPTIONS GRANTED TO EMPLOYEES	SCHEDULE OF FAIR VALUE OF OPTIONS GRANTED TO EMPLOYEES Year ended December 31 2023 2022 Expected life 5.125 6.5 5.125 6.5 Risk-free interest rates 3.58 4.73 1.79 2.88 Volatility 109.62 125.61 127.43 130.93 Dividend yield - -
SCHEDULE OF ALLOCATION OF TOTAL SHARE-BASED COMPENSATION EXPENSE	SCHEDULE OF ALLOCATION OF TOTAL SHARE-BASED COMPENSATION EXPENSE Year ended December 31 2023 2022 ($ in thousands) Cost of revenues $ 93 $ 72 Research and development 649 582 Sales and marketing 416 318 General and administrative 3,332 1,380 $ 4,490 $ 2,352

TAXES ON INCOME_ (Tables)

TAXES ON INCOME: (Tables)	12 Months Ended
	Dec. 31, 2023
Income Tax Disclosure [Abstract]
SCHEDULE OF COMPONENTS OF LOSS BEFORE INCOME TAXES	The components of loss before income taxes are as follows: SCHEDULE OF COMPONENTS OF LOSS BEFORE INCOME TAXES Year ended December 31 2023 2022 ($ in thousands) Loss before taxes on income: InspireMD, Inc. $ (5,772 ) $ (4,773 ) Subsidiaries (14,079 ) (13,690 ) $ (19,851 ) $ (18,463 )
SCHEDULE OF CHANGES IN VALUATION ALLOWANCE	The changes in the valuation allowance for the year ended December 31, 2023 and 2022 were as follows: SCHEDULE OF CHANGES IN VALUATION ALLOWANCE Year ended December 31 2023 2022 ($ in thousands) Balance at the beginning of the year $ 40,071 $ 39,212 Changes during the year: Losses during the year (including foreign exchange rate effect) 2,580 859 Balance at the end of the year $ 42,651 $ 40,071 f. Accounting for Uncertain Tax position
SCHEDULE OF RECONCILIATION OF UNCERTAIN TAX POSITIONS	The following is a reconciliation of the total amounts of the Company’s uncertain tax positions during the year ended December 31, 2023 and 2022 were as follows: SCHEDULE OF RECONCILIATION OF UNCERTAIN TAX POSITIONS Year ended December 31, 2023 2022 ($ in thousands) Balance at beginning of period $ 106 $ 89 Increase in uncertain tax positions because of tax positions taken during the year 62 17 Balance at end of period $ 168 $ 106
SCHEDULE OF OPEN TAX YEARS BY MAJOR JURISDICTION	A summary of open tax years by major jurisdiction is presented below: SCHEDULE OF OPEN TAX YEARS BY MAJOR JURISDICTION Jurisdiction Years U.S. 2020 2023 Israel 2019 2023 Germany 2020 2023
SCHEDULE OF DEFERRED INCOME TAX	SCHEDULE OF DEFERRED INCOME TAX 2023 2022 December 31, 2023 2022 ($ in thousands) Provision for vacation and recreation pay 68 45 R&D expenses 1,691 1,452 Operating lease right of use assets (339 ) (357 ) Operating lease liabilities 367 371 Share-based compensation 3,492 3,021 Carry forward tax losses 37,342 35,507 Accrued severance pay, net 30 32 Deferred tax assets noncurrent 42,651 40,071 Less-valuation allowance (42,651 ) (40,071 ) Deferred tax assets - -

SUPPLEMENTARY FINANCIAL STATE_2

SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Tables)	12 Months Ended
	Dec. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
SCHEDULE OF INVENTORIES	SCHEDULE OF INVENTORIES 2023 2022 December 31, 2023 2022 ($ in thousands) Finished goods $ 210 $ 179 Work in process 562 510 Raw materials and supplies 1,334 932 Total inventory $ 2,106 $ 1,621
SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUALS - OTHER	SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUALS - OTHER a. Accounts payable and accruals-other: 2023 2022 December 31, 2023 2022 ($ in thousands) Employees and employee institutions $ 2,188 $ 1,853 Accrued vacation and recreation pay 287 197 Accrued expenses 1,115 554 Clinical trial accrual 744 1,258 Current Operating lease liabilities 557 419 Other 190 130 Accounts Payable and Accruals - Other $ 5,081 $ 4,411

DISAGGREGATED REVENUE AND ENT_2

DISAGGREGATED REVENUE AND ENTITY WIDE DISCLOSURES (Tables)	12 Months Ended
	Dec. 31, 2023
Segment Reporting [Abstract]
SCHEDULE OF REVENUES ATTRIBUTED TO GEOGRAPHIC AREAS	Revenues are attributed to geographic areas based on the location of the customers. The following is a summary of revenues: SCHEDULE OF REVENUES ATTRIBUTED TO GEOGRAPHIC AREAS Year ended December 31, 2023 2022 ($ in thousands) Italy $ 1,195 $ 970 Germany 896 866 Russia 738 381 Other 3,376 2,954 $ 6,205 $ 5,171
SCHEDULE OF REVENUES ATTRIBUTED TO GEOGRAPHIC AREAS BY PRODUCT	By product: SCHEDULE OF REVENUES ATTRIBUTED TO GEOGRAPHIC AREAS BY PRODUCT Year ended December 31, 2023 2022 ($ in thousands) CGuard™ EPS $ 6,205 $ 5,123 MGuard Prime™ EPS - 48 $ 6,205 $ 5,171
SCHEDULE OF REVENUES ATTRIBUTED TO GEOGRAPHIC AREAS BY PRINCIPAL CUSTOMERS	By principal customers: SCHEDULE OF REVENUES ATTRIBUTED TO GEOGRAPHIC AREAS BY PRINCIPAL CUSTOMERS Year ended December 31, 2023 2022 Customer A 14 % 17 % Customer B 12 % 7 %

DESCRIPTION OF BUSINESS (Detail

DESCRIPTION OF BUSINESS (Details Narrative)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Russia and Belarus [Member] | Sales [Member] | Geographic Concentration Risk [Member]
Product Information [Line Items]
Sales percentage	13.50%	12.10%

SIGNIFICANT ACCOUNTING POLICI_3

SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)	12 Months Ended
	Dec. 31, 2023 USD ($) segment shares	Dec. 31, 2022 USD ($) shares
[custom:ResearchAndDevelopmentExpenseIncludingUSBasedClinicalTrialCost] | $	$ 3,300,000	$ 4,468,000
Significant Change in Unrecognized Tax Benefits, Nature of Event	the tax benefit is measured as the largest amount that is more than 50% likely to be realized upon ultimate settlement.
Advertising Expense | $	$ 426,000	$ 359,000
Weighted Average Number of Shares Outstanding, Diluted, Adjustment	9,612,502
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number	3,054,086	355,951
Number of Operating Segments | segment	1
Series C Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	74,978,006	2,741,355

SCHEDULE OF FINANCIAL ASSETS SU

SCHEDULE OF FINANCIAL ASSETS SUBJECT TO FAIR VALUE MEASUREMENTS (Details)	Dec. 31, 2023 USD ($)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable securities	$ 28,727,000
Fair Value, Recurring [Member] | US Government Agencies Debt Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable securities	29,383,000
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member] | US Government Agencies Debt Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable securities
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member] | US Government Agencies Debt Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable securities	29,383,000
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member] | US Government Agencies Debt Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable securities
Fair Value, Recurring [Member] | Money Market Funds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	7,094,000
Fair Value, Recurring [Member] | Money Market Funds [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	7,094,000
Fair Value, Recurring [Member] | Money Market Funds [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents
Fair Value, Recurring [Member] | Money Market Funds [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents

FAIR VALUE MEASUREMENTS (Detail

FAIR VALUE MEASUREMENTS (Details Narrative)	Dec. 31, 2023 USD ($)
Fair Value Disclosures [Abstract]
Cost of marketable securities	$ 28,727,000

SCHEDULE OF MARKETABLE SECURITI

SCHEDULE OF MARKETABLE SECURITIES (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Marketable Securities [Line Items]
Marketable securities	$ 29,383
US Government Agencies Debt Securities [Member]
Marketable Securities [Line Items]
Marketable securities	$ 29,383

SCHEDULE OF FAIR VALUE OF MARKE

SCHEDULE OF FAIR VALUE OF MARKETABLE SECURITIES CLASSIFIED BY MATURITY (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Investments, Debt and Equity Securities [Abstract]
Amounts maturing within one year	$ 24,523
Amounts maturing after one year through two years	4,860
Marketable securities	$ 29,383

SCHEDULE OF CHANGES IN FAIR VAL

SCHEDULE OF CHANGES IN FAIR VALUE OF MARKETABLE SECURITIES (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Investments, Debt and Equity Securities [Abstract]
Balance at beginning of the period
Additions	34,644
Sale or maturity	(6,000)
Interest Received	(38)
Changes in fair value	777
Balance at end of the period	$ 29,383

SCHEDULE OF PROPERTY PLANT AND

SCHEDULE OF PROPERTY PLANT AND EQUIPMENT (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Property, Plant and Equipment [Line Items]
Property plant and equipment, gross	$ 3,100	$ 2,825
Less - accumulated depreciation and amortization	(2,040)	(1,908)
Net carrying amount	1,060	917
Depreciation and amortization expenses	232,000	188,000
Computer Equipment [Member]
Property, Plant and Equipment [Line Items]
Property plant and equipment, gross	425	396
Office Furniture And Equipment [Member]
Property, Plant and Equipment [Line Items]
Property plant and equipment, gross	249	231
Machinery and Equipment [Member]
Property, Plant and Equipment [Line Items]
Property plant and equipment, gross	1,702	1,704
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property plant and equipment, gross	$ 724	$ 494

LIABILITY FOR EMPLOYEES RIGHT_2

LIABILITY FOR EMPLOYEES RIGHT UPON RETIREMENT (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Restructuring Cost and Reserve [Line Items]
Percentage of monthly deposits on salary	8.33%
Severance Type One [Member]
Restructuring Cost and Reserve [Line Items]
Severance expenses	$ 256,000	$ 241,000
Severance Type Two [Member]
Restructuring Cost and Reserve [Line Items]
Severance expenses	$ 116,000	$ 68,000

SCHEDULE OF SUPPLEMENTAL INFORM

SCHEDULE OF SUPPLEMENTAL INFORMATION RELATED TO LEASES (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Lease Agreements
Operating lease right-of-use assets	$ 1,473	$ 1,554
Current Operating lease liabilities	$ (557)	$ (419)
Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]	Accounts Payable, Other, Current	Accounts Payable, Other, Current
Non-current operating lease liabilities	$ (1,038)	$ (1,195)
Operating cash flows from operating leases (cash paid in thousands)	$ (429)	$ (436)
Weighted average remaining lease	3 years	4 years
Weighted average discount rate	9.73%	8.69%

SCHEDULE OF MATURITIES OF LEASE

SCHEDULE OF MATURITIES OF LEASE LIABILITIES (Details) $ in Thousands	Dec. 31, 2023 USD ($)
Lease Agreements
2024	$ 579
2025	584
2026	653
Total lease payments	1,816
Less imputed interest	(221)
Total	$ 1,595

LEASE AGREEMENTS (Details Narra

LEASE AGREEMENTS (Details Narrative) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Lease Agreements
Operating lease expense	$ 433,000	$ 442,000

COMMITMENTS AND CONTINGENT LI_2

COMMITMENTS AND CONTINGENT LIABILITIES (Details Narrative) - USD ($)	Feb. 03, 2021	Dec. 31, 2023
Commitments and Contingencies Disclosure [Abstract]
Distribution cost rate	50%	50%
Distribution reimbursement	$ 1,000,000

SCHEDULE OF ISSUANCE OF WARRANT

SCHEDULE OF ISSUANCE OF WARRANTS TO PURCHASE COMMON STOCK (Details)	Dec. 31, 2023 $ / shares shares
Class of Stock [Line Items]
Total Warrants	53,396,008
Series E Warrants [Member]
Class of Stock [Line Items]
Total Warrants	198,159
Weighted average exercise price | $ / shares	$ 27
Series F Warrants [Member]
Class of Stock [Line Items]
Total Warrants	433,878
Weighted average exercise price | $ / shares	$ 7.4250
Series G Warrants [Member]
Class of Stock [Line Items]
Total Warrants	1,092,344
Weighted average exercise price | $ / shares	$ 10.2300
Series H Warrants [Member]
Class of Stock [Line Items]
Total Warrants	12,914,086
Weighted average exercise price | $ / shares	$ 1.3827
Series I Warrants [Member]
Class of Stock [Line Items]
Total Warrants	12,914,078
Weighted average exercise price | $ / shares	$ 1.3827
Series J Warrants [Member]
Class of Stock [Line Items]
Total Warrants	12,914,086
Weighted average exercise price | $ / shares	$ 1.3827
Series K Warrants [Member]
Class of Stock [Line Items]
Total Warrants	12,914,078
Weighted average exercise price | $ / shares	$ 1.3827
Underwriter Warrants [Member]
Class of Stock [Line Items]
Total Warrants	15,299
Weighted average exercise price | $ / shares	$ 7.4250

SCHEDULE OF STOCK OPTIONS GRANT

SCHEDULE OF STOCK OPTIONS GRANTED (Details) - $ / shares	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Employee [Member]
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]
Number of options Outstanding - beginning of period	294,712,000	289,408,000
Weighted average exercise price Outstanding - beginning of period	$ 5.21	$ 5.29
Number of options Outstanding, Granted	1,097,250	7,841
Weighted average exercise price, Granted	$ 1.89	$ 2.61
Number of options Outstanding, Forfeited	(12,266)	(2,537)
Weighted average exercise price, Forfeited	$ 4	$ 5.70
Number of options Outstanding, Outstanding -end of period	1,379,696,000	294,712,000
Weighted average exercise price, Outstanding -end of period	$ 2.58	$ 5.21
Number of options Outstanding, Exercisable at the end of the period	215,709,000	123,115,000
Weighted average exercise price, Exercisable at the end of the period	$ 5.38	$ 5.51
Non Employee [Member]
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]
Number of options Outstanding - beginning of period	166,669,000	20,002,000
Weighted average exercise price Outstanding - beginning of period	$ 3.37	$ 6.90
Number of options Outstanding, Granted	625,000	146,667
Weighted average exercise price, Granted	$ 1.71	$ 2.89
Number of options Outstanding, Outstanding -end of period	791,669,000	166,669,000
Weighted average exercise price, Outstanding -end of period	$ 2.06	$ 3.37
Number of options Outstanding, Exercisable at the end of the period	84,667,000	35,667,000
Weighted average exercise price, Exercisable at the end of the period	$ 3.42	$ 3.61

SCHEDULE OF RESTRICTED STOCK GR

SCHEDULE OF RESTRICTED STOCK GRANTED TO EMPLOYEES (Details) - shares	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]
Number of restricted stock, Outstanding - beginning of period	355,951
Number of restricted stock, Outstanding - end of period	3,054,086	355,951
Employee [Member] | Restricted Stock [Member]
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]
Number of restricted stock, Outstanding - beginning of period	355,951	527,668
Number of restricted stock, Granted	2,914,340	45,494
Number of restricted stock, Forfeited	(29,695)	(10,832)
Number of restricted stock, Vested	(186,510)	(206,379)
Number of restricted stock, Outstanding - end of period	3,054,086	355,951

SCHEDULE OF RESTRICTED STOCK UN

SCHEDULE OF RESTRICTED STOCK UNIT GRANTED TO EMPLOYEES (Details) - shares	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]
Number of restricted stock, Outstanding - beginning of period	355,951
Number of restricted stock, Outstanding - end of period	3,054,086	355,951
Employee [Member] | Restricted Stock Units (RSUs) [Member]
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]
Number of restricted stock, Outstanding - beginning of period	237,078	237,078
Number of restricted stock, Granted	1,045,150
Number of restricted stock, Outstanding - end of period	1,282,228	237,078

SCHEDULE OF ADDITIONAL INFORMAT

SCHEDULE OF ADDITIONAL INFORMATION ABOUT ALL OPTIONS OUTSTANDING AND EXERCISABLE (Details)	12 Months Ended
	Dec. 31, 2023 $ / shares shares
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options outstanding	2,171,365
Weighted average remaining contractual life (years)	9 years 10 days
Options exercisable	300,376
Exercise Price One [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise price lower range | $ / shares	$ 1.15
Exercise price | $ / shares	$ 2.97
Options outstanding	1,786,211
Weighted average remaining contractual life (years)	9 years 3 months 10 days
Options exercisable	73,946
Exercise Price Two [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise price lower range | $ / shares	$ 3.30
Exercise price | $ / shares	$ 4.12
Options outstanding	227,932
Weighted average remaining contractual life (years)	8 years 6 months 10 days
Options exercisable	95,075
Exercise Price Three [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise price lower range | $ / shares	$ 4.95
Exercise price | $ / shares	$ 10.05
Options outstanding	153,169
Weighted average remaining contractual life (years)	7 years
Options exercisable	127,303
Exercise Price Four [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise price | $ / shares	$ 16.50
Options outstanding	4,053,000
Weighted average remaining contractual life (years)	6 years 3 days
Options exercisable	4,053

SCHEDULE OF FAIR VALUE OF OPTIO

SCHEDULE OF FAIR VALUE OF OPTIONS GRANTED TO EMPLOYEES (Details)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Risk-free interest rate, minimum	3.58%	1.79%
Risk-free interest rate, maximum	4.73%	2.88%
Volatility, minimum	109.62%	127.43%
Volatility, maximum	125.61%	130.93%
Dividend yield
Minimum [Member]
Expected life	5 years 1 month 15 days	5 years 1 month 15 days
Maximum [Member]
Expected life	6 years 6 months	6 years 6 months

SCHEDULE OF ALLOCATION OF TOTAL

SCHEDULE OF ALLOCATION OF TOTAL SHARE-BASED COMPENSATION EXPENSE (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Total share-based compensation expense	$ 4,490	$ 2,352
Cost of Sales [Member]
Total share-based compensation expense	93	72
Research and Development Expense [Member]
Total share-based compensation expense	649	582
Selling and Marketing Expense [Member]
Total share-based compensation expense	416	318
General and Administrative Expense [Member]
Total share-based compensation expense	$ 3,332	$ 1,380

EQUITY (Details Narrative)

EQUITY (Details Narrative) - USD ($)			12 Months Ended
		May 12, 2023	Dec. 31, 2023	Dec. 31, 2022	May 16, 2023
Subsidiary, Sale of Stock [Line Items]
Issuance of shares			7,731,618
Warrants to purchase common stock			53,396,008
Exercise of prefunded warrants			307,260
Preferred stock stated value	[1]
Capital stock shares authorized			155,000,000
Capital stock par value			$ 0.0001
Common stock shares authorized			150,000,000	150,000,000
Restricted Stock [Member]
Subsidiary, Sale of Stock [Line Items]
Weighted average of the remaining contractual life of vested and exercisable options			7 years 6 months 14 days
Aggregate intrinsic value of exercisable options			$ 10,983
Restricted Stock [Member] | Consultants [Member]
Subsidiary, Sale of Stock [Line Items]
Stock option exercise price			$ 1.95	$ 2.42
Share-Based Payment Arrangement, Option [Member] | Employees and Directors [Member]
Subsidiary, Sale of Stock [Line Items]
Stock option exercise price			1.65	2.33
Share-Based Payment Arrangement, Option [Member] | Consultants [Member]
Subsidiary, Sale of Stock [Line Items]
Stock option exercise price			1.50	$ 2.57
Restricted Stock Units (RSUs) [Member] | Consultants [Member]
Subsidiary, Sale of Stock [Line Items]
Stock option exercise price			$ 1.76
Employee And Non Employee Stock Option [Member]
Subsidiary, Sale of Stock [Line Items]
Unvested stock-based compensation			$ 7,180,000
Unvested stock-based compensation weighted-average period for recognition			11 months 19 days
Series C Preferred Stock [Member]
Subsidiary, Sale of Stock [Line Items]
Preferred stock conversion price		$ 1.3827
Preferred stock convertible shares issuable		5,668	7,952	2,284
Preferred stock outstanding			1,718	1,718	1,718
Preferred stock stated value			$ 10,997	$ 10,997
Preferred stock shares authorized			1,172,000	1,172,000
Pre-Funded Warrants [Member]
Subsidiary, Sale of Stock [Line Items]
Warrant exercise price		$ 0.0001
Warrants outstanding			15,254,623
Warrant [Member]
Subsidiary, Sale of Stock [Line Items]
Warrants to purchase common stock			307,271
Warrant exercise price		$ 1.3827
Preferred Stock Blank Check [Member]
Subsidiary, Sale of Stock [Line Items]
Preferred stock shares authorized			5,000,000
Private Placement [Member]
Subsidiary, Sale of Stock [Line Items]
Issuance of shares		10,266,270
Private placement		$ 42,200,000
Fees payable and other offering expenses		4,600,000
Gross proceeds from warrant exercises		$ 71,400,000
Private Placement [Member] | Pre-Funded Warrants [Member]
Subsidiary, Sale of Stock [Line Items]
Warrants to purchase common stock		15,561,894
Offering price per share		$ 1.6326
Private Placement [Member] | Warrant [Member]
Subsidiary, Sale of Stock [Line Items]
Warrants to purchase common stock		51,656,328
Offering price per share		$ 1.6327
Private Placement [Member] | Series H Warrants [Member]
Subsidiary, Sale of Stock [Line Items]
Warrants to purchase common stock		12,914,086
Private Placement [Member] | Series I Warrants [Member]
Subsidiary, Sale of Stock [Line Items]
Warrants to purchase common stock		12,914,078
Private Placement [Member] | Series J Warrants [Member]
Subsidiary, Sale of Stock [Line Items]
Warrants to purchase common stock		12,914,086
Private Placement [Member] | Series K Warrants [Member]
Subsidiary, Sale of Stock [Line Items]
Warrants to purchase common stock		12,914,078
At The Market Offering [Member] | Warrant [Member]
Subsidiary, Sale of Stock [Line Items]
Warrants to purchase common stock			53,396,008
[1]Represents an amount less than $1

RELATED PARTIES TRANSACTIONS (D

RELATED PARTIES TRANSACTIONS (Details Narrative) - USD ($)			12 Months Ended
	Jan. 01, 2024	Sep. 15, 2023	Dec. 31, 2023	Dec. 31, 2022
Related Party Transaction [Line Items]
Issuance of shares			7,731,618
Accrued fees			$ 55,000
Subsequent Event [Member]
Related Party Transaction [Line Items]
Issuance of shares	11,854
2021 Equity Incentive Plan [Member]
Related Party Transaction [Line Items]
Issuance of shares			32,125
Cash paid			$ 22,875
Related Party [Member]
Related Party Transaction [Line Items]
Consulting expenses			11,440
Consultancy Agreement [Member]
Related Party Transaction [Line Items]
Fixed hourly consulting fee		$ 50,000
Director [Member]
Related Party Transaction [Line Items]
Marketing services from related party			$ 788,000	$ 9,645,000
Non Employee Directors [Member]
Related Party Transaction [Line Items]
Issuance of shares			52,129

SCHEDULE OF COMPONENTS OF LOSS

SCHEDULE OF COMPONENTS OF LOSS BEFORE INCOME TAXES (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Loss before taxes on income	$ (19,851)	$ (18,463)
Parent Company [Member]
Loss before taxes on income	(5,772)	(4,773)
Subsidiaries [Member]
Loss before taxes on income	$ (14,079)	$ (13,690)

SCHEDULE OF CHANGES IN VALUATIO

SCHEDULE OF CHANGES IN VALUATION ALLOWANCE (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Income Tax Disclosure [Abstract]
Balance at the beginning of the year	$ 40,071	$ 39,212
Changes during the year: Losses during the year (including foreign exchange rate effect)	2,580	859
Balance at the end of the year	$ 42,651	$ 40,071

SCHEDULE OF RECONCILIATION OF U

SCHEDULE OF RECONCILIATION OF UNCERTAIN TAX POSITIONS (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Income Tax Disclosure [Abstract]
Uncertain tax positions balance at beginning of period	$ 106	$ 89
Increase in uncertain tax positions because of tax positions taken during the year	62	17
Uncertain tax positions balance at end of period	$ 168	$ 106

SCHEDULE OF OPEN TAX YEARS BY M

SCHEDULE OF OPEN TAX YEARS BY MAJOR JURISDICTION (Details)	12 Months Ended
	Dec. 31, 2023
UNITED STATES | Earliest Tax Year [Member]
Operating Loss Carryforwards [Line Items]
Open Tax Year	2020
UNITED STATES | Latest Tax Year [Member]
Operating Loss Carryforwards [Line Items]
Open Tax Year	2023
ISRAEL | Earliest Tax Year [Member]
Operating Loss Carryforwards [Line Items]
Open Tax Year	2019
ISRAEL | Latest Tax Year [Member]
Operating Loss Carryforwards [Line Items]
Open Tax Year	2023
GERMANY | Earliest Tax Year [Member]
Operating Loss Carryforwards [Line Items]
Open Tax Year	2020
GERMANY | Latest Tax Year [Member]
Operating Loss Carryforwards [Line Items]
Open Tax Year	2023

SCHEDULE OF DEFERRED INCOME TAX

SCHEDULE OF DEFERRED INCOME TAX (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Income Tax Disclosure [Abstract]
Provision for vacation and recreation pay	$ 68	$ 45
R&D expenses	1,691	1,452
Operating lease right of use assets	(339)	(357)
Operating lease liabilities	367	371
Share-based compensation	3,492	3,021
Carry forward tax losses	37,342	35,507
Accrued severance pay, net	30	32
Deferred tax assets noncurrent	42,651	40,071
Less-valuation allowance	(42,651)	(40,071)	$ (39,212)
Deferred tax assets

TAXES ON INCOME_ (Details Narra

TAXES ON INCOME: (Details Narrative) - USD ($) $ in Millions		12 Months Ended
	Dec. 29, 2016	Dec. 31, 2023	Dec. 31, 2017
Operating Loss Carryforwards [Line Items]
Federal corporate tax rate		21%
Revised tax rate on income of preferred enterprises	12%
Tax rate on income of beneficiary enterprises	6%	4%
Tax rate on income of beneficiary enterprises		90%
Net carry forward tax loss		$ 54	$ 35
Net loss carryforwards percentage		80%
Arising Before January One 2018 [Member]
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards expiration description		expires until 2038
Limited [Member]
Operating Loss Carryforwards [Line Items]
Net carry forward tax loss		$ 19
Minimum [Member]
Operating Loss Carryforwards [Line Items]
Corporate trade tax rate		7.50%
Maximum [Member]
Operating Loss Carryforwards [Line Items]
Corporate trade tax rate		16%
Israel Tax Authority [Member]
Operating Loss Carryforwards [Line Items]
Federal corporate tax rate		23%
Net carry forward tax loss		$ 107
Germany [Member]
Operating Loss Carryforwards [Line Items]
Federal corporate tax rate		15.825%
Corporate trade tax rate		17.15%

SCHEDULE OF INVENTORIES (Detail

SCHEDULE OF INVENTORIES (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Finished goods	$ 210	$ 179
Work in process	562	510
Raw materials and supplies	1,334	932
Total inventory	$ 2,106	$ 1,621

SCHEDULE OF ACCOUNTS PAYABLE AN

SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUALS - OTHER (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Employees and employee institutions	$ 2,188	$ 1,853
Accrued vacation and recreation pay	287	197
Accrued expenses	1,115	554
Clinical trial accrual	744	1,258
Current Operating lease liabilities	557	419
Other	190	130
Accounts Payable and Accruals - Other	$ 5,081	$ 4,411

SCHEDULE OF REVENUES ATTRIBUTED

SCHEDULE OF REVENUES ATTRIBUTED TO GEOGRAPHIC AREAS (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	$ 6,205	$ 5,171
ITALY
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	1,195	970
GERMANY
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	896	866
RUSSIAN FEDERATION
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	738	381
Other Countries [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	$ 3,376	$ 2,954

SCHEDULE OF REVENUES ATTRIBUT_2

SCHEDULE OF REVENUES ATTRIBUTED TO GEOGRAPHIC AREAS BY PRODUCT (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Revenue from External Customer [Line Items]
Revenue	$ 6,205	$ 5,171
C Guard E P S [Member]
Revenue from External Customer [Line Items]
Revenue	6,205	5,123
M Guard Prime E P S [Member]
Revenue from External Customer [Line Items]
Revenue		$ 48

SCHEDULE OF REVENUES ATTRIBUT_3

SCHEDULE OF REVENUES ATTRIBUTED TO GEOGRAPHIC AREAS BY PRINCIPAL CUSTOMERS (Details) - Sales [Member] - Customer Concentration Risk [Member]	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Customer A [Member]
Revenue, Major Customer [Line Items]
Percentage of revenues per major customer	14%	17%
Customer B [Member]
Revenue, Major Customer [Line Items]
Percentage of revenues per major customer	12%	7%